Scienta Lab
- Company typePrivate
- Founded2021
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Scienta Lab firmographics
Firmographics- Name
- Scienta Lab
- Legal name
- Scienta Lab
- Website
- https://scientalab.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Scienta Lab industry classification
Industry- Product category
- AI drug discovery software
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Scienta Lab is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Scienta Lab business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Customized Commercial Applications: The company offers customized commercial applications of EVA through partnerships with biopharmaceutical companies, providing tailored solutions for specific drug development programs.
- Open Model Access: An open version of the transcriptomic model is released for researchers at no cost, creating community adoption and potential pathway to commercial upsell.
- Partnership-based Licensing: Customized commercial applications through partnerships with biopharmaceutical companies for drug discovery and development programs.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Scienta Lab product offering
Product offeringCore offering
Scienta Lab builds and sells EVA, a 440M-parameter cross-species, multimodal AI foundation model purpose-built for immunology and inflammation drug discovery. EVA integrates transcriptomics and histology data to predict clinical trial success, support target prioritization, enable preclinical-to-human translation, and optimize patient stratification for biopharmaceutical R&D teams. The company delivers EVA as customized commercial applications through partnerships with biopharma companies.
Product overview
Scienta Lab provides EVA, a foundation model for immunology and inflammation drug discovery, powered by ImmunAtlas, their proprietary training dataset. EVA integrates over 500K transcriptomic samples and 20M histology tiles across human and mouse to predict clinical outcomes throughout the drug development pipeline. The platform addresses three key stages: target and mechanism prioritization (ranking programs by predicted clinical success probability), preclinical-to-human translation (predicting clinical efficacy from preclinical data), and patient stratification for trial optimization. EVA is offered as a commercial product via partnerships with biopharmaceutical teams, with an open transcriptomic version available for researchers.
Differentiator
Problem solved
Functional benefit
Brands
- EVA: Multimodal AI foundation model for immunology and inflammation drug discovery, trained on 500K+ transcriptomics samples and 20M histology tiles.
- ImmunAtlas
Products and services
- EVA EVA is a 440M-parameter cross-species, multimodal foundation model for immunology and inflammation drug discovery. It integrates transcriptomics (500K+ samples) and histology (20M+ tiles) from human and mouse, predicting clinical trial success, translational risk, and patient response to support target prioritization, preclinical-to-human translation, and trial optimization. Sold to biopharmaceutical R&D teams via customized commercial partnerships.
Quantifiable outcome
- Up to 2x performance gains compared to current industry standards across 40 benchmarked use cases
- +3 more outcomes
Companies that use Scienta Lab
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Scienta Lab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Scienta Lab partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered supporting and core.
- DataIA-ClustersupportingPartnership to advance multimodal and explainable AI research in collaboration with DataIA-Cluster, supporting Scienta Lab's development of foundation models for immunology.
- OSE ImmunotherapeuticscoreStrategic partnership to leverage artificial intelligence in precision immunotherapy. The collaboration aims to advance the understanding of underlying immune pathways causing immune-mediated and inflammatory diseases, potentially leading to more personalised treatments that improve patient health and quality of life.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
Scienta Lab competitors and assessment
Company assessmentBroad incumbents
- Isomorphic Labs: Isomorphic Labs is Alphabet's commercial drug discovery arm built on DeepMind's AlphaFold and related biology foundation models. It is a broad incumbent that competes with Scienta Lab at the foundation-model-for-drug-discovery layer but operates across all therapeutic areas rather than specializing in immunology.
- Schrödinger: Schrödinger provides physics-based and AI-driven molecular simulation software for drug discovery across pharma and biotech. It is a broad incumbent because it offers overlapping computational discovery capabilities, but operates as a horizontal software platform rather than focusing on immuno-inflammation patient-level prediction.
Direct peers
- Recursion Pharmaceuticals: Recursion builds AI foundation models across high-content biology and chemistry data to discover and develop new therapeutics. It is a direct peer because both companies train large-scale foundation models on proprietary multi-omic and imaging data to predict drug efficacy and prioritize targets.
- BenevolentAI: BenevolentAI builds AI foundation models on biomedical knowledge graphs and multi-omic data to identify novel targets, with an explicit focus on immunology and inflammation. It is a direct peer because both companies target immuno-inflammatory target prioritization and translational decision support.
- Iktos: Iktos is a French AI company applying generative models to small-molecule and macrocyclic drug design for pharma partners. It is a direct peer because it is a fellow French AI-for-drug-discovery vendor selling enterprise partnerships to biopharma, often on multi-year collaboration structures.
- Owkin: Owkin is a French AI-for-biopharma company applying multimodal AI to patient data for drug discovery and clinical research, with strong ties to European hospitals and pharma. It is a direct peer to Scienta Lab because both are European AI biotechs using multimodal biology data to support pharma R&D decisions.
- Generate Biomedicines: Generate Biomedicines builds generative AI foundation models for protein and biologic design, partnering with pharma on novel therapeutics. It is a direct peer because both companies pair proprietary training datasets with foundation-model architectures to predict therapeutic behavior and partner with biopharma on drug programs.
- Exscientia: Exscientia applies AI to accelerate small-molecule drug discovery and has expanded into patient-derived translational models. It is a direct peer because it sells AI-driven drug discovery and translational risk reduction to biopharma, overlapping with Scienta Lab's translational and clinical-trial optimization value proposition.
- Insitro: Insitro is a US-based AI drug discovery company building machine learning models on patient-derived data to predict clinical outcomes. It is a direct peer because both companies build foundation/AI models on multi-omic and clinical data to derisk pharma pipelines, with similar target prioritization and translational use cases.
Emerging players
- EvolutionaryScale: EvolutionaryScale develops large-scale AI foundation models for biology, including protein language and genomic models for research and pharma partners. It is an emerging player that competes in the same foundation-model-for-biology category as EVA, but with a broader biology focus rather than immunology specialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Scienta Lab social profiles
Digital presenceScienta Lab compliance and trust
Trust signalCompliance1 record
Scienta Lab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scienta Lab leadership team
Management profileNumber of profiles
Profiles6 records
Scienta Lab funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scienta Lab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scienta Lab
What does Scienta Lab do?
Scienta Lab builds and sells EVA, a 440M-parameter cross-species, multimodal AI foundation model purpose-built for immunology and inflammation drug discovery. EVA integrates transcriptomics and histology data to predict clinical trial success, support target prioritization, enable preclinical-to-human translation, and optimize patient stratification for biopharmaceutical R&D teams. The company delivers EVA as customized commercial applications through partnerships with biopharma companies.
Is Scienta Lab a public or private company?
Scienta Lab is a private company. It is classified as venture growth investor backed and is currently operating.
When was Scienta Lab founded?
Scienta Lab was founded in 2021. It employs 11 to 50 people.
Where is Scienta Lab based?
Scienta Lab is headquartered in Paris, France, in the Europe region.
How does Scienta Lab make money?
Three revenue lines are on record. Customized Commercial Applications are the primary driver. The others are open Model Access and partnership-based Licensing.
Who are Scienta Lab's main competitors?
Broad incumbents on record are Isomorphic Labs and Schrödinger. Direct peers are Recursion Pharmaceuticals, BenevolentAI, Iktos, Owkin, Generate Biomedicines, Exscientia and Insitro. EvolutionaryScale is listed as an emerging player.
Does Scienta Lab have an API?
No public API is recorded for Scienta Lab.
What industry is Scienta Lab in?
Scienta Lab's product category is AI drug discovery software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 5417 and its SIC code is 8731.